US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
GB9325445D0
(en)
*
|
1993-12-13 |
1994-02-16 |
Cortecs Ltd |
Pharmaceutical formulations
|
US5567592A
(en)
*
|
1994-02-02 |
1996-10-22 |
Regents Of The University Of California |
Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
|
GB9405304D0
(en)
*
|
1994-03-16 |
1994-04-27 |
Scherer Ltd R P |
Delivery systems for hydrophobic drugs
|
US5430021A
(en)
*
|
1994-03-18 |
1995-07-04 |
Pharmavene, Inc. |
Hydrophobic drug delivery systems
|
DE4443175A1
(de)
*
|
1994-12-05 |
1996-06-13 |
Jenapharm Gmbh |
Neue pulsatile Arzneiform
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
JPH10513200A
(ja)
*
|
1995-02-06 |
1998-12-15 |
ナノシステムズ エルエルシー |
可消化オイル又は脂肪酸中の微粒子分散物である化合物の製剤
|
EP0831870A4
(en)
*
|
1995-06-07 |
1998-09-16 |
Avmax Inc |
USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
|
US5665386A
(en)
*
|
1995-06-07 |
1997-09-09 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US5716928A
(en)
*
|
1995-06-07 |
1998-02-10 |
Avmax, Inc. |
Use of essential oils to increase bioavailability of oral pharmaceutical compounds
|
US6024980A
(en)
*
|
1996-06-28 |
2000-02-15 |
Mcneil-Ppc, Inc. |
Multiphase soft gelatin dosage form
|
AU695734B2
(en)
|
1996-07-08 |
1998-08-20 |
Penwest Pharmaceuticals Co. |
Sustained release matrix for high-dose insoluble drugs
|
US6458373B1
(en)
*
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US20030008919A1
(en)
*
|
1999-06-03 |
2003-01-09 |
Jean-Baptiste Roullet |
Use of retinoids to treat high blood pressure and other cardiovascular disease
|
JP2002500190A
(ja)
|
1998-01-08 |
2002-01-08 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
海洋海綿から誘導されるキネシンモーターモジュレーター
|
US7030155B2
(en)
*
|
1998-06-05 |
2006-04-18 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6200968B1
(en)
*
|
1998-08-06 |
2001-03-13 |
Cephalon, Inc. |
Particle-forming compositions containing fused pyrrolocarbazoles
|
FR2782006B1
(fr)
*
|
1998-08-07 |
2002-04-19 |
Gattefosse Ets Sa |
Composition a liberation prolongee apte a former une micro-emulsion
|
PL348193A1
(en)
|
1998-12-11 |
2002-05-06 |
Pharmasolutions |
Self-emulsifying compositions for drugs poorly soluble in water
|
US6057289A
(en)
*
|
1999-04-30 |
2000-05-02 |
Pharmasolutions, Inc. |
Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
|
US20020132001A1
(en)
*
|
2000-05-11 |
2002-09-19 |
Garthwaite Susan M. |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US8568766B2
(en)
*
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US6664230B1
(en)
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
CA2480826C
(fr)
*
|
2002-04-09 |
2012-02-07 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
US7670612B2
(en)
|
2002-04-10 |
2010-03-02 |
Innercap Technologies, Inc. |
Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
US20040077621A1
(en)
*
|
2002-08-08 |
2004-04-22 |
Academia Sinica |
Antioxidants
|
EP1594512A4
(en)
*
|
2003-02-11 |
2007-07-11 |
Kemia Inc |
COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
AU2005204391A1
(en)
*
|
2004-01-14 |
2005-07-28 |
Lavipharm Laboratories, Inc. |
Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
|
WO2005077331A1
(en)
*
|
2004-02-11 |
2005-08-25 |
Athpharma Limited |
Chronotherapeutic compositions and methods of their use
|
US8741635B2
(en)
|
2004-05-12 |
2014-06-03 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of cell isolation
|
EP2371846B1
(en)
|
2005-03-10 |
2013-12-04 |
Ben Gurion University of the Negev Research and Development Authority Ltd. |
Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
|
US8648045B2
(en)
|
2005-03-10 |
2014-02-11 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
VDAC1 compositions and methods of use thereof for regulating apoptosis
|
EP2269623A1
(en)
|
2005-04-29 |
2011-01-05 |
The Regents of The University of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
WO2006135985A1
(en)
|
2005-06-24 |
2006-12-28 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
|
US8691272B2
(en)
*
|
2005-12-30 |
2014-04-08 |
Intelgenx Corp. |
Multilayer tablet
|
CN101426536A
(zh)
|
2006-01-20 |
2009-05-06 |
妇女儿童健康研究院公司 |
治疗、预防和诊断骨病变的方法
|
EP2004680B1
(en)
*
|
2006-04-06 |
2017-06-21 |
Ben-Gurion University Of The Negev |
N-terminal vdac variants and uses thereof
|
WO2007123153A1
(ja)
*
|
2006-04-19 |
2007-11-01 |
Ono Pharmaceutical Co., Ltd. |
経口投与用カプセル
|
MY153288A
(en)
*
|
2006-06-28 |
2015-01-29 |
Hovid Berhad |
An effective pharmaceutical carrier for poorly bioavailable drugs
|
WO2008015959A1
(fr)
*
|
2006-08-01 |
2008-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Composition pharmaceutique permettant une meilleure absorption d'une substance pharmacologiquement active
|
CA2667925A1
(en)
*
|
2006-10-27 |
2008-05-02 |
Janssen Pharmaceutica N.V. |
Dry granulated pharmaceutical compositions and methods for producing same
|
AU2008279550B2
(en)
*
|
2007-06-21 |
2012-08-09 |
Angelica Therapeutics, Inc. |
Modified toxins
|
SI2185198T1
(sl)
|
2007-08-02 |
2015-04-30 |
Gilead Biologics, Inc. |
Inhibitorji LOX in LOXL2 ter njihova uporaba
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
EP2682400B1
(en)
*
|
2007-08-28 |
2017-09-20 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US9149481B2
(en)
*
|
2007-10-03 |
2015-10-06 |
Wista Laboratories Ltd. |
Therapeutic use of diaminophenothiazines
|
EP2268297A4
(en)
*
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
US8715722B2
(en)
*
|
2008-05-12 |
2014-05-06 |
Capsugel Belgium Nv |
Capsule with air-vents
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
CN102711809B
(zh)
|
2009-08-17 |
2015-09-30 |
特雷康制药公司 |
使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
|
US8221753B2
(en)
*
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
ES2363965B1
(es)
*
|
2009-11-20 |
2013-01-24 |
Gp Pharm S.A. |
Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US9249189B2
(en)
|
2010-01-18 |
2016-02-02 |
Albany Medical College |
Alpha-fetoprotein “ring and tail” peptides
|
KR101930179B1
(ko)
|
2010-08-27 |
2018-12-17 |
길리아드 바이오로직스, 인크. |
매트릭스 메탈로프로테이나제 9에 대한 항체
|
BR112013009196A2
(pt)
|
2010-10-15 |
2020-08-25 |
The Trustees Of Columbia University In The City Of New York |
usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
|
AU2012249301A1
(en)
|
2011-04-29 |
2013-11-21 |
Kinemed, Inc. |
Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
|
CA2850187C
(en)
*
|
2011-09-29 |
2021-12-07 |
Plx Pharma Inc. |
Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
|
CN107184974A
(zh)
|
2012-02-29 |
2017-09-22 |
吉利德生物制剂公司 |
抗基质金属蛋白酶9的抗体
|
BR112014021477A2
(pt)
|
2012-02-29 |
2018-06-12 |
Gilead Sciences Inc |
anticorpos para metaloproteinase de matriz 9
|
CN104203263A
(zh)
|
2012-03-01 |
2014-12-10 |
耶达研究与发展有限公司 |
利用HSP60衍生肽再生胰岛β细胞
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
TW201406707A
(zh)
|
2012-05-04 |
2014-02-16 |
Acucela Inc |
用以治療糖尿病性視網膜病變及其他眼部疾病之方法
|
JP2015524397A
(ja)
|
2012-07-20 |
2015-08-24 |
ラトローブ ユニヴァーシティ |
診断及び処置の方法
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
CA2903869A1
(en)
|
2013-03-14 |
2014-09-25 |
Uab Research Foundation |
Apolipoprotein e dosing regimen for treating atherosclerosis
|
US10017551B2
(en)
|
2013-03-15 |
2018-07-10 |
The Regents Of The University Of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
CA2904357C
(en)
|
2013-03-15 |
2020-09-22 |
Intrinsic Lifesciences Llc |
Anti-hepcidin antibodies and uses thereof
|
JP2016519651A
(ja)
|
2013-03-15 |
2016-07-07 |
アンジェリカ セラピューティックス,インク. |
改質された毒素
|
WO2015011711A1
(en)
|
2013-07-25 |
2015-01-29 |
The National Institute for Biotechnology in the Negev Ltd. |
Short peptides derived from vdac1, compositions and methods of use thereof
|
US9873724B2
(en)
|
2013-12-20 |
2018-01-23 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Pro-angiogenic peptides and peptide conjugates
|
EP3110847A1
(en)
|
2014-02-27 |
2017-01-04 |
Gilead Sciences, Inc. |
Antibodies to matrix metalloproteinase 9 and methods of use thereof
|
BR112016028750A2
(pt)
|
2014-06-11 |
2017-11-14 |
Gilead Sciences Inc |
?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
|
US10793614B2
(en)
|
2014-07-17 |
2020-10-06 |
Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. |
Antagonists of fish reproduction
|
US10155790B2
(en)
|
2014-07-17 |
2018-12-18 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antagonists of neurokinin B in fish reproduction
|
AU2015298263B2
(en)
|
2014-07-31 |
2020-05-14 |
Anji Pharmaceuticals, Inc. |
ApoE mimetic peptides and higher potency to clear plasma cholesterol
|
WO2016019333A1
(en)
|
2014-07-31 |
2016-02-04 |
Kinemed, Inc. |
The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
JP2017537084A
(ja)
|
2014-11-12 |
2017-12-14 |
トラコン ファーマシューティカルズ、インコーポレイテッド |
抗エンドグリン抗体及びその用途
|
AU2016315873B2
(en)
|
2015-09-04 |
2022-08-18 |
Primatope Therapeutics Inc. |
Humanized anti-CD40 antibodies and uses thereof
|
US10149887B2
(en)
|
2015-10-23 |
2018-12-11 |
Canbas Co., Ltd. |
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
|
US10617738B2
(en)
|
2015-10-27 |
2020-04-14 |
The University Of Queensland |
Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
US20170174788A1
(en)
|
2015-12-17 |
2017-06-22 |
Gilead Sciences, Inc. |
Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
|
WO2017177179A1
(en)
|
2016-04-08 |
2017-10-12 |
Gilead Sciences, Inc. |
Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
|
US11154591B2
(en)
|
2016-10-14 |
2021-10-26 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating alcohol abuse disorder
|
JP2020506923A
(ja)
|
2017-01-30 |
2020-03-05 |
ハドソン インスティテュート オブ メディカル リサーチ |
治療方法
|
WO2018213803A1
(en)
|
2017-05-19 |
2018-11-22 |
Neon Therapeutics, Inc. |
Immunogenic neoantigen identification
|
KR102344616B1
(ko)
|
2017-05-30 |
2021-12-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
항-더블코르틴-유사 키나제 1 항체 및 사용 방법
|
JP7054418B2
(ja)
|
2017-11-08 |
2022-04-13 |
ビオンテック ユーエス インコーポレイテッド |
T細胞を製造する組成物及び方法
|
JP2022536684A
(ja)
|
2019-06-11 |
2022-08-18 |
マイエロイド・セラピューティクス,インコーポレーテッド |
マクロファージ特異的エンゲージャー組成物およびその使用方法
|
CA3141084A1
(en)
|
2019-06-12 |
2020-12-17 |
Vikram JUNEJA |
Neoantigen compositions and uses thereof
|
MX2022011743A
(es)
*
|
2020-03-26 |
2022-12-08 |
Plx Opco Inc |
Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
|
EP4196135A4
(en)
|
2020-08-13 |
2024-08-21 |
Biontech Us Inc |
COMPOSITIONS AND METHODS FOR PRODUCING T CELLS
|
JP2023549140A
(ja)
|
2020-11-04 |
2023-11-22 |
マイエロイド・セラピューティクス,インコーポレーテッド |
操作されたキメラ融合タンパク質組成物およびその使用方法
|